Coeptis Therapeutics, Inc. (COEP)
NASDAQ: COEP · IEX Real-Time Price · USD
0.292
-0.010 (-3.44%)
Jul 17, 2024, 4:30 PM EDT - Market closed

Company Description

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company.

It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes.

Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology.

The company is also developing a multi-antigen CAR T technology licensed from the University of Pittsburgh, and the GEAR cell therapy and companion diagnostic platforms, which are developing with VyGen-Bio and medical researchers at the Karolinska Institute.

Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease.

The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Coeptis Therapeutics, Inc.
Coeptis Therapeutics logo
Country United States
Founded 2017
Industry Biotechnology
Sector Healthcare
Employees 5
CEO David Mehalick

Contact Details

Address:
105 Bradford Rd, Suite 420
Wexford, Pennsylvania 15090
United States
Phone 724-934-6467
Website coeptispharma.com

Stock Details

Ticker Symbol COEP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001819663
CUSIP Number 19207C104
ISIN Number US19207A1088
Employer ID 84-3998117
SIC Code 2834

Key Executives

Name Position
David Mehalick Co-Founder, Chairman of the Board, Chief Executive Officer and President
Christine Elise Sheehy Co-Founder and Vice President of Compliance and Corporate Secretary
Daniel Alexander Yerace Co-Founder, Vice President of Operations and Director
Brian Cogley M.B.A. Chief Financial Officer
Dr. Colleen Delaney M.D., M.Sc. CSO and Chief Medical Officer

Latest SEC Filings

Date Type Title
Dec 14, 2022 15-12G Securities registration termination
Nov 8, 2022 10-Q Quarterly Report
Oct 28, 2022 8-K Current Report
Sep 30, 2022 DEFM14A Filing
Sep 21, 2022 8-K Current Report
Sep 21, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 19, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 16, 2022 PREM14A Filing
Sep 7, 2022 253G2 Acc-no: 0001493152-21-027927 (33 Act)
Sep 7, 2022 8-K Current Report